Best Life Sciences Tech Companies in Ile de France, France
The 70 best Life Sciences Tech companies in Ile de France, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Owkin.
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Tech companies in Ile de France
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Owkin 🦄 AI generative biology company to create the new standard of biology reasoning 89AI top 18%Innovation top 21%Patents top 21%Funding top 23% All 12 signals ▾AItop 18% Innovationtop 21% Patentstop 21% Fundingtop 23% Growthtop 23% Moattop 25% Globaltop 34% Fin. healthtop 37% Talenttop 38% Markettop 40% Techtop 46% Newsbottom 27% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Innovation: 49 patents (top 29% of patent-holders) · 39 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 89/100 | $321M | 3 mo ago | 47 | Gilles Wainrib Co-Founder | Series B | WebflowApple iCloud MailGoogle Workspace+21 | 25 patents AI-driven medical imaging analysis and federated learning for cancer prognosis and treatment response | 1 launch |
| 2 | Enterome Developer of immunomodulatory drugs targeting cancer and immune diseases | $130M | 71 mo ago | 70 | — | Series E | — | 188 patents Microbiome-derived antigenic peptides for cancer immunotherapy and B‑cell malignancy treatment | — |
| 3 | Aqemia Provider of an AI and quantum physics to discover therapeutic molecules 60Funding top 28%AI top 30%Moat top 38%Tech top 39% All 11 signals ▾Fundingtop 28% AItop 30% Moattop 38% Techtop 39% Innovationtop 44% Growthtop 48% Patentstop 49% Talentbottom 49% Marketbottom 44% Globalbottom 36% Newsbottom 18% Funding: Raised $62.7M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) AI: Classified as an AI company · Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 60/100 | $63M | 14 mo ago | 60 | Maximilien Levesque Founder & CEO | Series A | WebflowApple iCloud MailGoogle Workspace+15 | 4 patents Small‑molecule inhibitors of METTL3 and MAP4K1 for epigenetic therapeutic applications | — |
| 4 | Depixus Provider of solutions for single-molecule genetic and epigenetic sequencing | $47M | 54 mo ago | 68 | Gordon Hamilton Co-Founder & CEO | Series A | — | 53 patents Patents concentrated in chemistry & materials | — |
| 5 | Inato AI-based patient recruitment platform | $36M | 38 mo ago | 49 | Philippe Ravaud Co-Founder | Series A | — | — | — |
| 6 | Bioptimus Developer of AI foundation model to transform biological research 64AI top 20%Talent top 23%Funding top 33%Growth top 35% All 9 signals ▾AItop 20% Talenttop 23% Fundingtop 33% Growthtop 35% Moattop 42% Techbottom 49% Globalbottom 38% Marketbottom 36% Newsbottom 18% AI: Classified as an AI company Talent: 6 named leaders on record · 6 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 64/100 | $35M | 17 mo ago | — | Jean-Philippe Vert Co-Founder | Series A | WebflowGSAPMicrosoft Advertising+16 | — | 2 launchs · 1 partnership |
| 7 | Adents Provider of serialization software solutions mainly for the pharmaceutical industry | $27M | 119 mo ago | 31 | Christophe Devins Co Founder | Series C | — | — | — |
| 8 | DeepLife Provider of AI-based drug discovery and omics analysis tool for researchers 37AI top 22%Funding top 40%Moat top 45%Patents top 48% All 8 signals ▾AItop 22% Fundingtop 40% Moattop 45% Patentstop 48% Innovationtop 49% Talentbottom 49% Globalbottom 39% Marketbottom 24% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $16.4M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $16M | 18 mo ago | 10 | Jonathan Baptista Co-Founder & CEO | Series A | — | 4 patents AI-driven graph analytics and generative digital twin simulation for complex system modeling | 1 award |
| 9 | Iktos Artificial Intelligence for new drug design | $16M | 39 mo ago | 55 | Nicolas Do Huu Co-Founder & CTO | Series A | PrismicNode.jsThree.js+14 | — | — |
| 10 | Kadrige Solutions and services for promotion, information, training and remote management to the pharmaceutical… | $15M | 165 mo ago | 50 | Olivier Cadou Founder & CEO | Acquired | — | 11 patents Networked remote screen control and automatic communication session recording. | — |
| 11 | WhiteLab Genomics Provider of drug discovery and development platform | $10M | 45 mo ago | 29 | David Del Bourgo CEO co-founder | Series A | SkolengoSentryApple iCloud Mail+20 | 4 patents ML-driven phenotype prediction and cell‑surface protein identification for functional genomics | — |
| 12 | Kyron.bio Developer of bioproduction platform for drug discovery and development 27Growth top 35%Funding top 45%Talent bottom 49%Tech bottom 45% All 6 signals ▾Growthtop 35% Fundingtop 45% Talentbottom 49% Techbottom 45% Globalbottom 36% Marketbottom 17% Growth: Fresh capital in last 24 mo Funding: Raised $7.7M across 4 rounds · 4 rounds over 3 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 27/100 | $8M | 12 mo ago | 6 | Emilia McLaughlin Founder | Seed | WixSentryBootstrap+10 | — | — |
| 13 | Scienta Lab Provider of data-driven models to support drug development and clinical strategies | $4M | 30 mo ago | 7 | Camille Bouget Co-Founder & CEO | Series A | WebflowGSAPSwiper+10 | — | — |
| 14 | Ariana Pharma Develops clinical data analysis and diagnostic testing solutions. | $2M | 215 mo ago | 22 | — | Series A | WordPressMySQLPHP+24 | — | — |
| 15 | Primaa Provider of AI-based software for detection of cancer 40AI top 35%Talent top 38%Funding top 42%Moat top 48% All 7 signals ▾AItop 35% Talenttop 38% Fundingtop 42% Moattop 48% Techbottom 38% Globalbottom 37% Marketbottom 35% AI: Product described with: ai-based, artificial intelligence Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $2M | 7 mo ago | 35 | Stephane Sockeel Chief Scientific Officer and Co-Founder | Series B | WordPressMySQLPHP+19 | — | 2 awards |
| 16 | Klineo Digital clinical data and trial management tool for doctors and researchers | $2M | 25 mo ago | — | Nicolas Drizard CTO & Co-Founder | Seed | SentryNode.jsNextAuth.js+20 | — | 4 partnerships |
| 17 | Iconeus Digital animal brain imaging and analysis device for researchers | $2M | 44 mo ago | 30 | — | Funding Raised | WordPress Site EditorWordPressMySQL+20 | 25 patents Medical ultrasound systems for real-time brain vascular and physiological monitoring | — |
| 18 | GreenTropism Provider of software components for mainstream and industrial spectroscopy | $1M | 106 mo ago | 13 | Anthony Boulanger Founder & CEO | Seed | — | 31 patents Rapid pathogen detection in biological fluids using surface-enhanced Raman spectroscopy | — |
| 19 | Discngine Provider of services and solutions for the life sciences industry | $1M | 97 mo ago | 68 | — | Series A | — | — | 1 launch |
| 20 | Notocord Life sciences software publisher | $647K | 77 mo ago | 11 | — | Acqui-Hired | — | — | — |
| 21 | Triacys Triacys offers technology solutions and services for clinical trials. | $485K | 132 mo ago | — | Hertsel Adhoute Founder | Seed | — | — | — |
| 22 | MAK-SYSTEM Laboratory information management software for blood, plasma, tissue and cell centers | — | 76 mo ago | 117 | Simon Kiskovski Founder | Late Stage | WordPressSentryMySQL+23 | — | — |
| 23 | Cegedim Digital data flow management services | — | 77 mo ago | 6,469 | Laurent Labrune CEO | Public | Apple iCloud MailNode.jsVimeo+13 | 4 patents Remote network-based presentation and control of display screens | — |
Top 12 Life Sciences Tech companies in Ile de France
#1
Owkin 🦄Series B · Paris, Ile de France · founded 2016 · 47 employees$321.1Mraised▾
AI generative biology company to create the new standard of biology reasoning. The company is creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. It is building the operating system for biology a platform in general-purpose biology intelligence.
- Mar 2026Series B$33M
- Jan 2023Grant (prize money)$216.4K
- Jun 2022Series B$80M
- Nov 2021Series B$180M
#2
Series A · Paris, Ile de France · founded 2019 · 60 employees$62.7Mraised▾
Provider of an AI and quantum physics to discover therapeutic molecules. The software uses AI-Based technology for screening different small molecules, knowing its physical properties helping in upstream processing and drug discovery. The software also helps in determining therapeutic targets responsible for particular diseases.
- Apr 2025Grant (prize money)$7.4M
- Dec 2024Series A$40.1M
- Jan 2024Series A$32.5M
- Oct 2022Series A$29.1M
#3
Series A · Paris, Ile de France · founded 2024$35Mraised▾
Developer of AI foundation model to transform biological research. The company's model would integrate different scales of biological data, from molecules to cells to tissues, to reveal new insights. It fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- Jan 2025Series A$41M
- Feb 2024Seed$35M
#4
Series B · Paris, Ile de France · founded 2018 · 35 employees$2.2Mraised▾
Primaa is a developer of AI-based software for automated and accurate histological diagnoses. The software is designed to assist pathology diagnosis. The product is based on image processing and artificial intelligence.
- Oct 2025Series B$8.2M
- Nov 2024Series A$5.4M
- Oct 2019Seed$2.2M
- Jul 2019Grant (prize money)$44.8K
#5
Seed · Paris, Ile de France · founded 2022 · 6 employees$7.7Mraised▾
Developer of bioproduction platform for drug discovery and development. It offers a platform that offers a technology that enables the yield of therapeutic proteins produced in mammalian cell factories by harnessing efficient processes from diverse organisms to revolutionize drug production.
- May 2025Seed$6.2M
- Jul 2023Grant (prize money)$84.3K
- Jul 2023Grant (prize money)$81.9K
- 2022Seed$1.3M
#6
Series A · Paris, Ile de France · founded 2019 · 10 employees$16.4Mraised▾
Provider of AI-based drug discovery and omics analysis tool for researchers. The company has developed tools that are AI-enabled for the process of drug discovery. The tool assists in provided insights for target protein for the drug for an individual patient. The tools use machine learning technology to identify molecular triggers for the drug and target identification. It has features to process biological data, tools for genomic screening, and more.
- Dec 2024Series A$10.5M
- Oct 2022Series A$5.9M
#7
Series A · Paris, Ile de France · founded 2016 · 49 employees$35.5Mraised▾
AI-based patient recruitment platform. The company offers an AI-based patient recruitment system, intending to accelerate recruitment by enabling data-driven site selection. It provides end-to-end personalized site selection by identifying potential sites, gathering information on each site, analyzing recruitment capabilities, modeling and optimizing recruitment, and more.
- Mar 2023Series A$20M
- Feb 2020Series A$14M
- Nov 2017Seed$1.5M
#8
Series E · Paris, Ile de France · founded 2008 · 70 employees$129.7Mraised▾
Developer of immunomodulatory drugs targeting cancer and immune diseases. The company develops drugs based on the ability to de-code the gut microbiome’s interaction with the immune system. The company has developed two technology platforms which include OncoMimics therapeutic cancer vaccines, and EndoMimics an oral bioactive to treat inflammatory and autoimmune diseases.
- Jun 2020Series E$52.3M
- Jan 2018Conventional Debt$48.1M
- Jan 2018Series D$38.5M
- Apr 2016Series C$16.4M
#9
Series A · Paris, Ile de France · founded 2012 · 68 employees$47Mraised▾
Provider of solutions for single-molecule genetic and epigenetic sequencing. The platform technology SIMDEQ (SIngle-molecule Magnetic Detection and Quantification), initially developed at École Normale Supérieure (ENS), exploits the biophysical properties of DNA and RNA to enable genetic and epigenetic sequencing. The DNA and RNA are converted into a 'hairpin' library that is immobilized on a magnetic bead. Under the influence of a magnetic field, these hairpins are 'zipped' and 'unzipped'.
- Dec 2021Series A$34.5M
- Oct 2021Grant (prize money)$115.6K
- Nov 2018Grant (prize money)$2.3M
- Dec 2016Grant (prize money)$52.7K
#10
Series A · Paris, Ile de France · founded 2016 · 55 employees$16.3Mraised▾
Iktos offers artificial intelligence for new drug design. The company is using artificial intelligence technology for ligand-based de novo drug design and focusing on multiparametric optimization (MPO). Their platform can design new, druggable and synthesizable molecules according to particular criteria. Their technology is based on deep learning algorithms.
- Mar 2023Series A$16.3M
#11
Series A · Gif sur Yvette, Ile de France · founded 2021 · 7 employees$4.3Mraised▾
Provider of data-driven models to support drug development and clinical strategies. The company harnesses the AI predictive platform which is used to model immune-mediated inflammatory diseases and predict patient diagnosis, prognosis, and response to treatment. Also, it is applicable to clinical development and clinical strategies.
- Dec 2023Series A$4.3M
#12
Seed · Paris, Ile de France · founded 2021$2.1Mraised▾
Digital clinical data and trial management tool for doctors and researchers. The company has developed software that assists professionals to manage clinical trial documents and patient information. It can be used for trial recruitment and other clinical processes.
- Apr 2024Seed$2.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in France
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,220 France-affiliated papers.
- Centre National de la Recherche Scientifique280
- Inserm169
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement144
- Ministry of Agriculture118
- AgroParisTech36
- Gene3→26
- Genome2→14
- Antibody1→10
- Cell culture1→10
- Mutant1→10
- Gene2→30
- Agriculture1→20
- Selection (genetic algorithm)2→18
- Resistance (ecology)2→16
- Population1→12
- Agriculture2→13
- Antibiotic resistance3→12
- Population1→9
- Public health1→8
- Context (archaeology)2→9
Where biotechnology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in France
France biotechnology patent filing is cooling — 34,222 filings from 8,000 assignees (2016–2025), led by Centre NAT RECH Scient, INST NAT Sante RECH MED, Sanofi; annual filings 3501→2745.
- Centre NAT RECH Scient10040
- INST NAT Sante RECH MED8292
- Sanofi3990
- Pasteur Institut3416
- Agronomique INST NAT RECH1331
- Cellectis1320
- PF Medicament1203
- Commissariat Energie Atomique1151
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.